Cardio-Metabolic Diseases

Our cardio-metabolic team is committed to delivering a range of high quality and validated in vitro and in vivo models for key cardio-metabolic disease (CMD) risk factors and etiologies. This selection allows drug developers to test therapeutic efficacy to prevent or reverse insulin resistance, pre-diabetes, type 2 diabetes, NASH/NAFLD and cardiovascular disease and heart failure (with model of both HFrEF and HFpEF). With high translatability of results, each model is customizable and can be executed in conjunction with many of our standard drug development services.  

  • Myocardial infraction models
  • Transversal aortic constriction
  • Osmotic angiotensin II 
  • HFpEF model
  • Diabetic cardiomyopathy
  • NIF model